Analyst rating coverage is not available for IVF yet.
12-MONTH PRICE TARGET
—
Average target across 0 active firms as of Nov 18, 2026 vs $2.21 current
Highest Target—
Average Target—
Lowest Target—
IVF analyst recommendation trends
86420
Nov
Dec
Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Strong BuyBuyNeutralSellStrong Sell
RATING
JUN
JUL
AUG
SEP
OCT
NOV
Strong Buy
0
0
0
0
0
0
Buy
0
0
0
0
0
0
Neutral
0
0
0
0
0
0
Sell
0
0
0
0
0
0
Strong Sell
0
0
0
0
0
0
Total
0
0
0
0
0
0
As of Nov 18, 2026, 0 of 0 active firms rate IVF a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
IVF EPS & revenue forecast
EPS · NEXT QUARTER
$-17.60
Range $-17.60 – $-17.60 · 1 analysts
Next period, 1 analysts expect INVO Fertility, Inc. to earn $-17.60 a share (range $-17.60 – $-17.60), versus — a year earlier. Full-year consensus is $-2227.20, growing to $-32.00 the year after.
REVENUE · NEXT QUARTER
$3.3M
Range $3.3M – $3.3M · 1 analysts · +111% YoY
Revenue is expected to reach $3.3M (range $3.3M – $3.3M), +110.6% year-over-year. Full-year consensus is $10.4M, rising to $16.5M next year.
Top analysts covering INVO Fertility, Inc.
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on IVF.
#1
Jason McCarthy
Maxim Group · Rank #567
Buy
$20.00+805.0% to target
Overall win rate
30%
+ Follow
IVF stock forecast FAQ
Who is the most accurate analyst covering IVF?+
Among analysts who currently cover IVF, Jason McCarthy of Maxim Group has the strongest overall Quantellect track record (Rank #567). Their current call is Buy with a $20.00 target.
What is INVO Fertility, Inc.'s projected EPS for next quarter?+
The consensus estimate is $-17.60 per share (range $-17.60 – $-17.60) across 1 analysts. Full-year EPS is projected at $-2227.20, rising to $-32.00 the following year.
How much revenue is INVO Fertility, Inc. expected to report next quarter?+
Consensus revenue is $3.3M (range $3.3M – $3.3M). Full-year revenue is projected at $10.4M, growing to $16.5M next year.
Have analysts been upgrading or downgrading IVF lately?+
As of Nov 18, 2026, 0 of 0 active firms rate IVF a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their IVF calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.